SCHEMBL4883159

SCHEMBL4883159

Cc1ccc(C(=O)CCC(=O)N(C)C)cc1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.63
GSK3B P49841 1/20 0.52
CTNNB1 P35222 4/20 0.51
WNT3A P56704 4/20 0.51
MEN1 O00255 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
POLB P06746 1/20 0.47
TP53 P04637 1/20 0.47
THRB P10828 1/20 0.47
ATM Q13315 1/20 0.46
PKM P14618 1/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 1/20 0.45
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
PAX8 Q06710 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16922186 1.00 KMT2A (0.63) KMT2AGSK3BCTNNB1WNT3AMEN1
SCHEMBL16552778 0.85 KMT2A (0.83) KMT2AGSK3BCTNNB1WNT3AMEN1
SCHEMBL15223664 0.84 KMT2A (0.58) KMT2AGSK3BCTNNB1WNT3AMEN1
SCHEMBL3966037 0.83 NPC1 (0.60) KMT2ACTNNB1MEN1NPC1RAB9A
SCHEMBL940512 0.82 KMT2A (0.63) KMT2AGSK3BCTNNB1WNT3AMEN1
SCHEMBL1201428 0.82 NPC1 (0.60) KMT2AGSK3BMEN1NPC1RAB9A
SCHEMBL1258744 0.81 KMT2A (0.59) KMT2AGSK3BCTNNB1WNT3AMEN1
SCHEMBL30552473 0.80 MMP1 (0.61) KMT2AGSK3BMEN1NPC1RAB9A
SCHEMBL5458640 0.78 GSR (0.64) KMT2AGSK3BCTNNB1WNT3AMEN1
SCHEMBL822848 0.78 KMT2A (0.70) KMT2AGSK3BCTNNB1WNT3AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050054669-A1 Process for the synthesis of zolpidem RANBAXY LABORATORIES LIMITED (IN) 2005-03-10 US claimed
CN-114105974-A Preparation method of zolpidem 鲁南制药集团股份有限公司 2022-03-01 CN disclosed
CN-114057729-A Preparation method of zolpidem 鲁南制药集团股份有限公司 2022-02-18 CN disclosed
US-20080262025-A1 Processes for the Preparation of Zolpidem and its Hemitartrate RANBAXY LABORATORIES LIMITED (IN) 2008-10-23 US disclosed
US-20080262025-A1 Processes for the Preparation of Zolpidem and its Hemitartrate RANBAXY LABORATORIES LIMITED (IN) 2008-10-23 US disclosed
US-20080262025-A1 Processes for the Preparation of Zolpidem and its Hemitartrate RANBAXY LABORATORIES LIMITED (IN) 2008-10-23 US disclosed
EP-1395586-B1 METHOD FOR THE PRODUCTION OF ZOLPIDEM BOEHRINGER INGELHEIM PHARMA (DE) 2007-02-14 EP disclosed
EP-1660496-A1 PROCESS FOR THE SYNTHESIS OF ZOLPIDEM Ranbaxy Laboratories Limited (IN) 2006-05-31 EP disclosed
WO-2006008636-A2 PROCESSES FOR THE PREPARATION OF ZOLPIDEM AND ITS HEMITARTRATE RANBAXY LABORATORIES LIMITED (IN) 2006-01-26 WO disclosed
US-6921839-B2 Synthesis of N,N-dimethyl-3-(4-methyl) benzoyl propionamide a key intermediate of zolpidem RANBAXY LABORATORIES LIMITED (IN) 2005-07-26 US disclosed
US-6921839-B2 Synthesis of N,N-dimethyl-3-(4-methyl) benzoyl propionamide a key intermediate of zolpidem RANBAXY LABORATORIES LIMITED (IN) 2005-07-26 US disclosed
US-20050054669-A1 Process for the synthesis of zolpidem RANBAXY LABORATORIES LIMITED (IN) 2005-03-10 US disclosed
US-20050054669-A1 Process for the synthesis of zolpidem RANBAXY LABORATORIES LIMITED (IN) 2005-03-10 US disclosed
WO-2005010002-A1 PROCESS FOR THE SYNTHESIS OF ZOLPIDEM RANBAXY LABORATORIES LIMITED (IN) 2005-02-03 WO disclosed
WO-2005010002-A1 PROCESS FOR THE SYNTHESIS OF ZOLPIDEM RANBAXY LABORATORIES LIMITED (IN) 2005-02-03 WO disclosed
EP-1370515-A2 SYNTHESIS OF N,N-DIMETHYL-3-(4-METHYL) BENZOYL PROPIONAMIDE, A KEY INTERMEDIATE OF ZOLPIDEM RANBAXY LABORATORIES, LTD. (IN) 2003-12-17 EP disclosed
WO-2002018303-A3 SYNTHESIS OF N,N-DIMETHYL-3-(4-METHYL) BENZOYL PROPIONAMIDE, A KEY INTERMEDIATE OF ZOLPIDEM RANBAXY LAB LTD (IN) 2003-10-02 WO disclosed
WO-2002018303-A2 SYNTHESIS OF N,N-DIMETHYL-3-(4-METHYL) BENZOYL PROPIONAMIDE, A KEY INTERMEDIATE OF ZOLPIDEM RANBAXY LABORATORIES LIMITED (IN) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054669-A1 Process for the synthesis of zolpidem TET2, KDM5B, HNMT KMT2A 57/4885GSK3B 3343/4885CTNNB1 3993/4885
US-20080262025-A1 Processes for the Preparation of Zolpidem and its Hemitartrate HTR5A, GABRA5, HTR4 KMT2A 141/4885GSK3B 684/4885CTNNB1 2489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.